article Open AccessTop 1% cited

Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study

The Lancet Oncology · 2020 · Vol. 21(5) · pp. 671–684

Ghassan K. Abou‐Alfa✉(Memorial Sloan Kettering Cancer Center)Vaibhav Sahai(University of Michigan)Antoine Hollebecque(Institut Gustave Roussy)Gina M. Vaccaro(Providence Portland Medical Center)Davide Melisi(University of Verona)Raed Moh’d Taiseer Al-Rajabi(The University of Kansas Cancer Center)Andrew Scott Paulson(Baylor University Medical Center)Mitesh J. Borad(WinnMed)David Gallinson(Morristown Medical Center)Adrian Murphy(Johns Hopkins University)Do‐Youn Oh(Seoul National University Hospital)Efrat Dotan(Fox Chase Cancer Center)Daniel V.T. Catenacci(University of Chicago)Eric Van Cutsem(KU Leuven)Tao Ji(Incyte (United States))Christine Lihou(Incyte (United States))Hui‐Ling Zhen(Incyte (United States))Luis Féliz(Incyte (United States))Arndt Vogel(Medizinische Hochschule Hannover)

View via DOI Publisher page

Cholangiocarcinoma and Gallbladder Cancer Studies Fibroblast Growth Factor Research Histiocytic Disorders and TreatmentsMedicineClinical endpointFibroblast growth factor receptorInternal medicineFibroblast growth factorPhases of clinical researchCancerToxicityGastroenterologyOncology

MeSH terms

Progression-Free SurvivalAdultAgedFemaleFibroblast Growth FactorsHumansMaleMiddle AgedMorpholinesNeoplasm MetastasisNeoplasm Recurrence, LocalPyrimidinesPyrrolesOncogene Proteins, FusionReceptors, Fibroblast Growth Factor

Citations

1,533

FWCI

194.43

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

References

THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL